期刊
JOURNAL OF NEUROIMMUNOLOGY
卷 166, 期 1-2, 页码 180-188出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jneuroim.2005.06.003
关键词
interferon-beta; multiple sclerosis; bioactivity; neutralizing antibody; gene expression
Many multiple sclerosis (MS) patients treated with IFN beta develop anti-IFN beta antibodies, which can interfere with the bioactivity of the injected cytokine, i.e., antibody-mediated decreased bioactivity (ADB). The precise levels of anti-IFN beta antibodies inducing decreased bioactivity is unknown. We repeatedly used a bioactivity measure, gene expression of MxA or GEM, and correlated bioactivity with measures of binding and neutralizing antibodies. The binding antibody assay was a capture ELISA, and the neutralizing antibody (NAb) assay was a cytopathic effect (CPE) assay. 27% (17/64) of patients repeatedly sampled developed critical ADB. Bioactivity as determined by GEM correlated negatively with NAb titer, and bioactivity that had been lost with the development of NAbs returned if NAb levels diminished. These data reveal that the GEM assay is a useful adjunct in the management of MS patients treated with IFN beta, and that lost bioactivity returns when anti-IFN beta antibody levels diminish. (C) 2005 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据